Masimo Corporation (Masimo), a US based medical devices company, announced that three of the nation's top hospital Group Purchasing Organizations (GPOs) have established a new Pulse CO-Oximetry category and extended multi-year supplier agreements for Masimo SET pulse oximetry and Masimo Rainbow SET Pulse CO-Oximetry products.
Establishing a new Pulse CO-Oximetry product category on national contract portfolios allows Novation, MedAssets Supply Chain Systems, and Amerinet to offer an innovative new selection of patient monitoring devices clinically proven to help clinicians provide earlier detection of potentially life-threatening conditions. This enables customer hospitals and healthcare facilities to purchase breakthrough noninvasive blood monitoring products that may increase patient safety, improve the quality of care, and reduce the cost of care at a great value.
Mark Miriani, president,MedAssets Supply Chain Systems, stated: “MedAssets remains focused on the important trends and issues facing the healthcare community and we recognize the importance of providing advanced technology solutions and innovative new product offerings to our customers. Pulse CO-Oximetry has the potential to improve patient safety and clinical performance, thereby delivering greater value to both hospitals and patients. We are proud to be among the first to offer Masimo Rainbow SET Pulse CO-Oximetry products on contract to our customers, creating the opportunity for measurable performance improvement as well as cost savings.”
Brad Morgan, director of material management, The Heart Hospital Baylor Plano, stated: “We are pleased that our GPO is making medical technologies like Masimo Rainbow SET available.”
Martin Allard, Anesthesiologist, Loma Linda University Medical Center, stated: “Pulse CO-Oximetry has enormous potential. We chose the Masimo Rainbow SET Pulse CO-Oximetry platform because it provides us with the unique ability to noninvasively, continuously and immediately measure a variety of blood constituents, in addition to standard pulse oximetry measurements. Having this amount of vital physiologic data available at our fingertips has allowed us to make more rapid diagnoses, initiate intervention and treatment earlier, and make better care decisions for patients.”
Rick Fishel, Masimo president of Americas and Worldwide OEM Business, stated: “Novation, MedAssets, and Amerinet are leading the way toward a new paradigm of potentially more effective and efficient patient care enabled by state-of-the-art noninvasive medical devices. These new GPO agreements reinforce the clinical and operational adoption of Masimo Rainbow SET Pulse CO-Oximetry as an emerging standard of care.”